FDA Warning and Removal of Rosiglitazone From VA National Formulary
After the FDA warning and removal of rosiglitazone from the VA National Formulary, glucose control may have declined among those discontinuing rosiglitazone without receiving replacement medication.
Implementation of an Inpatient Management and Discharge Strategy for Patients With Community-acquired Pneumonia
